Form 4: Liquidia CDO Sanjeev Khindri Granted 34,274 RSUs

Liquidia Corp's Chief Development Officer, Sanjeev Khindri, was granted 34,274 Restricted Stock Units, increasing his total unvested RSU holdings to 71,266.

Summary

• Sanjeev Khindri, Chief Development Officer of Liquidia Corp (LQDA), was granted 34,274 Restricted Stock Units (RSUs) on January 16, 2026.
• These RSUs convert into common stock on a one-for-one basis.
• The grant price for these RSUs was $0.
• Following this transaction, Mr. Khindri beneficially owns a total of 71,266 unvested RSUs.
• The vesting schedule for the newly granted 34,274 RSUs is: 25% will vest on January 11, 2027, and 6.25% will vest every three months thereafter.
• The total 71,266 RSUs include the 34,274 RSUs granted on January 16, 2026, and 36,992 RSUs granted on February 10, 2025, none of which have vested as of the date of this Form 4.

Sentiment

Score: 7

Explanation: The RSU grant is a positive event for executive alignment and retention, but it is a routine compensation matter and not indicative of significant operational or financial news for the company.

Positives

• The grant of Restricted Stock Units aligns the Chief Development Officer's interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• RSU grants are a common form of executive compensation, indicating standard corporate practices.

Future Outlook

The future outlook for the Chief Development Officer's equity ownership includes the vesting of 25% of the newly granted RSUs on January 11, 2027, followed by quarterly vesting of 6.25% thereafter, subject to continued employment.

Industry Context

The grant of Restricted Stock Units to a key executive like the Chief Development Officer is a standard practice in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize talent by linking their long-term compensation to the company's performance and shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, are a common component across the biotechnology and pharmaceutical sectors, aligning with industry standards for incentivizing leadership.
• The vesting schedule, with an initial cliff and subsequent quarterly vesting, is a typical structure seen in similar companies to ensure long-term commitment.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Development Officer's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: This type of compensation can serve as a benchmark or incentive for other employees, reinforcing a performance-based culture.

Next Steps

• The RSUs will begin vesting on January 11, 2027, with subsequent vesting occurring quarterly.

Key Dates

Recommendation

This Form 4 reports a routine RSU grant to an executive, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis or warrant a change in recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Liquidia Corp, LQDA, Restricted Stock Units, RSU grant, Insider transaction, Executive compensation, Form 4, Sanjeev Khindri